¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"very late activation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activation gate
    °³¹æ°ü¹®
  • activation process
    Ȱ¼ºÈ­°úÁ¤
  • complement activation
    º¸Ã¼È°¼ºÈ­, µµ¿òüȰ¼ºÈ­
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼ºÈ­
  • ventricular activation
    ½É½ÇȰ¼ºÈ­
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement activation
    µµ¿òüȰ¼º, º¸Ã¼È°¼º
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼º
  • ventricular activation
    ½É½ÇÈïºÐ
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • polyclonal B cell activation
    B¼¼Æ÷ ´Ù(¼ö)Ŭ·ÐȰ¼º, B¼¼Æ÷ ¿©·¯¹«¸®È°¼º
  • polyclonal activation
    ´Ù(¼ö)Ŭ·ÐȰ¼º, ¿©·¯¹«¸®È°¼º
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • late period of limb buds
    ÆÈ´Ù¸®½ÏÈıâ
  • late postprandial postgastrectomy syndrome
    Èıâ½ÄÈļº À§ÀýÁ¦ÈÄÁõÈıº(ý­Ñ¢ãÝý­àõêÖôîð¶ý­ñøý¦ÏØ).
  • late reaction
    Áö¿¬¹ÝÀÀ.
  • late relapse
    ¸¸±âÀç¹ß.
  • late responding
    ¸¸±â¹ÝÀÀ
  • late responding tissue
    ¸¸±â¹ÝÀÀÁ¶Á÷
  • late rickets
    ¸¸¹ß±¸·çº´.
  • late rickets
    ¸¸¹ß ±¸·çº´.
  • late syphilis<³ª>lues tarda
    ÈĹ߸ŵ¶
  • late systolic murmur
    ¼öÃ฻±â¼º ÀâÀ½.
  • late uniform deceleration
    Èıâµî°¨¼Ó.
  • late-onset depression
    Áö¹ß¼º¿ì¿ïÁõ(òÀÛ¡àõéØê¦ñø),¸¸¹ß¼º¿ì¿ïÁõ(عۡàõ~)(º´)
  • lateral cutaneous branch of posterior intercostal artery<³ª> ramus cutaneus late ralis artery interc
    (ÈÄ´Á°£µ¿¸ÆÀÇ) ¿ÜÃøÇÇÁö.
  • lateral intermuscular septum of arm<³ª> septum intermusculare brachii late
    ¿ÜÃø »ó¿Ï±Ù°£ Áß°Ý.
  • lateral pterygoid lamina<³ª> lateral lamina of pterygoid process ; lamina late ralis processus ptery
    Àͻ󵹱â¿ÜÃøÆÇ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Arrenius activation energy
    ¾Æ·¹´Ï¿ì½º Ȱ¼º(üÀàõ)¿¡³ÊÁö
  • complement activation
    º¸Ã¼ Ȱ¼ºÈ­(ÜÍô÷üÀàõûù)
  • contact activation cofactor
    "Á¢ÃËȰ¼º º¸ÀÎÀÚ(ïÈõºüÀàõÜÍì×í­), (ÔÒ) high molecular weight kininogen"
  • energy of activation
    Ȱ¼ºÈ­(üÀàõûù) ¿¡³ÊÁö
  • fatty acid activation
    Áö¹æ»ê Ȱ¼ºÈ­ (ò·Û¸ß«üÀàõûù)
  • feed-forward activation
    ¾Õ¸ÔÀÓ È°¼ºÈ­ (üÀàõûù)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • neutron activation alalysis
    Áß¼ºÀÚ ¹æ»çÈ­ºÐ¼®(ñéàõí­Û¯ÞÒûùÝÂà°)
  • reciprocal activation
    »óº¸ Ȱ¼ºÈ­(ßÓÜÍüÀàõûù)
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
VLCFA Very Long Chain Fatty Acids
VLDL Very Low Density Lipoprotein
PVD patient very disturbed; peripheral vascular disease; portal vein dilation; posterior vitreous detach...
VGH very good health
VHDL very high density lipoprotein
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AVHRR Advanced Very High Resolution Radiometer
beta VLDL beta very low density lipoprotein
beta-VLDL beta migrating very low density lipoprotein
VLBW Very Low Birth Weight
VLCD Very Low Calorie Diet
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • late effet
    ÈÄÀ¯ È¿°ú
    ¾î¶² ¾à¹°À» »ç¿ëÇßÀ» ¶§ ½ÇÁ¦ ±× ¾à¹°ÀÇ È¿°ú´Â ¾Æ´ÏÁö¸¸ µû¶ó¼­ ¹ß»ýÇÏ´Â ¾ç¼º Áõ»ó.
  • late eruption
    ¸ÍÃâ Áö¿¬, ¸¸±â»ýÄ¡
    Ä¡¾ÆÀÇ ¸ÍÃâ±â°¡ Àü¸éÀûÀ¸·Î ¶Ç´Â ÀϺΠ´Ê¾îÁö´Â °ÍÀ» ¸»ÇÑ´Ù. ¿øÀÎÀ¸·Î¼­´Â Ä¡°üÀÇ ÀÌ»óÀ¸·Î Ä¿´Ù¶õ Ä¡¾Æ, ¸ÍÃâºÎÀÇ Çù¼Ò, Ä¡¹èÀÇ ÀüÀ§, Ä¡¾ÆÁ¾À̳ª ³¶Æ÷ µîÀÌ ÀÖ´Ù.
  • late generalization
    ¸¸±â ¸¸¿¬
    °áÇÙÀÌ Àü½ÅÀ¸·Î È®»êµÇ¾î À²¸³ °áÇÙÀ¸·Î ¹ßÀüÇÏ´Â ÇÑ °¡ÁöÇüÀ¸·Î óÀ½ °¨¿°µÈ ºÎÀ§°¡ ÈÞÁöÇϰí Àå±â °áÇÙÁõÀÌ µÈ ÈÄ ±× º´¼Ò¸¦ Ãâ¹ßÁ¡À¸·Î Ç÷Ç༺À¸·Î È®ÀåµÇ´Â °ÍÀÌ´Ù.
  • late luteal phase dysphoric disorder
    ¸»±â Ȳü±â ºÒÄè Àå¾Ö
  • late middle age
    Àå³â±â
    40´ë ÈĹݿ¡¼­ 50´ë ÈĹݱîÁöÀÇ ³ªÀÌ.
  • late opening click
    °³±¸ ¸»±â Ŭ¸¯À½
    ÇÏ¾Ç °úµÎÀÇ Àü¹æ ȰÁÖ ¿îµ¿ÀÌ ³¡³ª±â ¹Ù·Î Á÷Àü¿¡ °üÀý¿¡¼­ »ý±â´Â ¼Ò¸®.
  • late postprandial hypoglycemia
    ½ÄÈÄ Èıâ ÀúÇ÷´çÁõ
    À§ ÀýÁ¦ ÈÄ º¸°Ô µÇ´Â Èı⠴ýÇÎ Áõ»óÀÇ Çϳª.
  • late reaction
    Áö¿¬ ¹ÝÀÀ
  • late schizophrenia
    ¸¸¹ß ºÐ¿­Áõ
    40¼¼ ÀÌÈÄ¿¡ ÃʹßÇÏ´Â Á¤½ÅºÐ¿­Áõ. ¿©¼º¿¡°Ô ¸¹À¸¸ç ¿¹ÈÄ´Â ÀϹÝÀûÀ¸·Î ¾çÈ£Çϰí ÁßÁõÀÇ °áÇÔÀ» ³²±â´Â °æ¿ì´Â Àû´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
late reaction A local or generalised response that begins 24 to 48 hours after exposure to an antigen.
See: cell-mediated reaction.
Synonym: contact hypersensitivity, delayed hypersensitivity, late reaction, tuberculin-type hypersensitivity.
(05 Mar 2000)
late replicating chromosome A chromosome (often anomalous) that is shown, e.g., by incorporation of a labelled nucleotide, to undergo delayed duplication preliminary to mitosis; formerly used as a means of distinguishing members of a group of chromosome's.
(05 Mar 2000)
late rickets <pathology> A condition marked by softening of the bones (due to impaired mineralisation, with excess accumulation of osteoid), with pain, tenderness, muscular weakness, anorexia and loss of weight, resulting from deficiency of vitamin D and calcium.
Origin: Gr. Malakia = softness
(18 Nov 1997)
late seizure A seizure that occurs greater than one week after a craniocerebral trauma or CNS insult.
(05 Mar 2000)
late seral species Shade tolerant species, primarily vine maple shrubs and western red cedar and western hemlock trees. These species follow the mid seral species in natural succession.
(05 Dec 1998)
late seral treatment A treatment in which late seral species will be established after thinning.
(05 Dec 1998)
late-successional forest Forest seral stages which include mature and old- growth age classes.
(05 Dec 1998)
late-successional reserve An area of forest where the management objective is to protect and enhance conditions of late successional and old-growth forest ecosystems.
(05 Dec 1998)
late syphilis Involvement of the cardiovascular or central nervous system, or the development of a gumma in any organ, due to infection with Treponema pallidum; usually several years to 2-3 decades after the initial infection.
Synonym: tertiary syphilis.
(05 Mar 2000)
late systole The interval in the cardiac rhythm immediately preceding diastole.
Synonym: late systole.
(05 Mar 2000)
activation <radiobiology> Activation occurs when a particle interacts with an atomic nucleus, shifting the nucleus into an unstable state, and causing it to become radioactive.
In fusion research, where deuterium-tritium is a common fuel mixture, the neutron released when (D + T) combine to form (4He + n) can activate the reactor structure. In this case the 4He is inert, the neutron sticks to another nucleus, and the neutron + nucleus reaction creates an actvation product. Sometimes called radioactivation.
See: activation product, activation analysis.
(09 Oct 1997)
activation analysis <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays.
Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many.
(09 Oct 1997)
activation energy <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state.
(06 May 1997)
activation product <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.)
(09 Oct 1997)
amino acid activation The first step of protein synthesis, whereby an amino acid reacts with adenosine triphosphate in the presence of aminoacyl RNA synthetase to produce an amino acid adenylate, which provides the energy necessary for the attachment of the amino acid to a specific transfer RNA molecule.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á